Funding outlook shifts in fight against antimicrobial resistance

LONDON — Twenty-two research-based biopharmaceutical companies — including AstraZenica, GlaxoSmithKline and Merck — invested more than $2 billion in research and development to counter antimicrobial resistance in 2016, according to a survey released Thursday, potentially upending widespread perceptions that the private sector is trailing institutional donors in tackling AMR.